PP
CCCC icon

PDT Partners’s C4 Therapeutics CCCC Stock Holding History

PDT Partners’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,432
Closed -$58.9K – 596
2023
Q2 		$58.9K Sell
21,432
-57,091
-73% -$184K 0.01% 545
2023
Q1 		$247K Buy
78,523
+21,151
+37% +$125K 0.03% 487
2022
Q4 		$338K Buy
57,372
+15,685
+38% +$130K 0.05% 458
2022
Q3 		$366K Sell
41,687
-66,376
-61% -$689K 0.06% 526
2022
Q2 		$815K Buy
+108,063
New +$951K 0.07% 456

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PDT Partners's CCCC Position: Q3 2023 in Review

PDT Partners sold out of C4 Therapeutics (CCCC) in Q3 2023, closing a stake of 21,432 shares — an estimated $58.9K sold.

PDT Partners first reported a position in CCCC in Q2 2022 and held it in 5 quarters. The position peaked at $815K in Q2 2022. 83 funds tracked by Wall St. Rank hold CCCC as of Q3 2023.

  • PDT Partners reported no remaining C4 Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PDT Partners sold 21,432 C4 Therapeutics shares in Q3 2023, an estimated $58.9K.
  • PDT Partners first reported a position in C4 Therapeutics in Q2 2022 and held it in 5 quarters.
  • PDT Partners's C4 Therapeutics position peaked at $815K in Q2 2022.
  • 83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2023.

Based on PDT Partners's 13F filing for Q3 2023, filed 14 Nov 2023.